Use of hydroxychloroquine in Japan

Journal of Rheumatology

Volumn 39, Issue 6, 2012, Pages 1296-

  Kishimoto, Mitsumasa ^a   Deshpande, Gautam A ^a   Yokogawa, Naoto ^b   Buyon, Jill P ^c   Okada, Masato ^a  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^c NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; HYDROXYCHLOROQUINE;

ARTHRITIS; AUTOFLUORESCENCE; CHRONIC DISEASE; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG SAFETY; DRUG USE; ELECTRORETINOGRAM; EPILEPSY; FATIGUE; HUMAN; JAPAN; JAPANESE; LETTER; MALARIA; NEPHRITIS; OPTICAL COHERENCE TOMOGRAPHY; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA DISEASE; RETINA TOXICITY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIRHEUMATIC AGENTS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYCHLOROQUINE; JAPAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATIC DISEASES;

EID: 84861792456     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111569     Document Type: Letter

References (19)

1. Wallace D. The history of antimalarials. Lupus 1996;5 Suppl 1:S2-3. (Pubitemid 26196733)
2. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three medications. N Engl J Med 1996;334:1287-91. (Pubitemid 26138009)
3. Dixon JS, Pickup ME, Bird HA, Lee MR, Wright V, Downie WW. Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis. Ann Rheum Dis 1981;40:480-8. (Pubitemid 12231938)
4. Kim WU, Seo YI, Park SH, Lee WK, Lee SK, Paek SI, et al. Treatment with cyclosporine switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:514-7.
5. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjogren syndrome: Its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999;58:253-6. (Pubitemid 29191659)
6. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus etythematosus: A systematic review. Ann Rheum Dis 2010;69:20-8.
7. Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7. (Pubitemid 44737176)
8. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009;11:R109.
9. Jung H, Robba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010;62:863-8.
10. Shinjo SK, Bonfa E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin America inception cohort. Arthritis Rheum 2010;62:855-62.
11. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80. (Pubitemid 40663939)
12. Pons-Estel GJ, Alarcon GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV. Data from a multiethnic US cohort. Arthritis Rheum 2009;61:830-9.
13. Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010;69:1827-30.
14. Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. Arch Ophthalmol 1957;57:451-7.
15. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478-80.
16. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF; American Academy of Ophthalmology, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82. (Pubitemid 34700934)
17. College of Ophthalmologists. Chloroquine, hydroxychloroquine and the eye. London: College of Ophthalmologists; 1993.
18. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415-22.
19. Yokogawa N, Kato Y, Sugii S, Inada S. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). Mod Rheumatol 2011 Aug 14 [E-pub ahead of print].